Wenger Vieli with Creoptix in its acquisition by Malvern Panalytical
Malvern Panalytical, an England based company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has completed the acquisition of Creoptix, a specialist bioanalysis sensor company. Creoptix provides cutting edge tools for molecular interaction analysis through its WAVEsystem of next-generation bioanalytical instruments. The WAVEsystem offers a breakthrough level of kinetics analysis.
The acquisition forms a critical part of Malvern Panalytical’s strategy to expand its capabilities in support of drug discovery.
Founded in 2009, Creoptix is headquartered in Wädenswil, near Zurich with a US subsidiary in the Boston area.
Wenger Vieli advised the shareholders of Creoptix on this transaction regarding all legal aspects. The team was led by Beat Speck (partner, m&a / corporate, pictured) and included Barbara Brauchli (partner / tax), Anna Tomaschek (associate, m&a / corporate), and Matea Brezovic (junior lawyer, m&a / corporate).
